There's a great unfilled need for something that raises HDLNiacin expected to grow as heart treatment Jan 23, 2007
For every pharmaceutical company developing a new drug, the reality is that current therapy is pretty goodHeart drugs pretty effective Nov 18, 2005
We took a scientific gamble in publishing (the JAMA) article because we didn't have a lot of information, but it is to JAMA's credit that the journal decided that the information belonged in the public domainMerck issues worldwide recall of Vioxx Sep 30, 2004
Ask a patient if he or she is more concerned about the 2 percent risk for an abnormal liver function test vs. a 28 percent reduction in mortality. What do you think the answer will beSuper low cholesterol saves lives Mar 08, 2004
Steven E. Nissen (born 1949), a cardiologist, is chairman of cardiovascular medicine at the Cleveland Clinic. Nissen received his B.S. and his M.D. from University of Michigan. He completed his cardiovascular training at the University of Kentucky.
Nissen first gained prominence in 1987 when he developed techniques to thread miniaturized ultrasound imaging devices into a patient's heart to reveal the exact composition of plaques causing the early stages of artery damage; the technique is now called intravascular ultrasound (IVUS). This allowed much easier evaluation of anticholesterol medications.
His efforts in 2004 linked COX-2 inhibitors such as celecoxib (Celebrex) and Merck's rofecoxib (Vioxx) with heart attacks, and prevented Merck's similar product, etoricoxib, from being approved. In 2005, his analysis of the experimental diabetes drug muraglitazar, from Bristol-Myers Squibb, exposed its adverse cardiac risk profile, leading to withdrawal of the drug despite initial strong approval from a Food and Drug Administration advisory panel.